Pharmaceutics_R&D
Follow
Find tag "NIH"
3.6K views | +0 today
Pharmaceutics_R&D
Pharmaceutical companies R&D specifically in neuroscience, CNS disease, pain and electrophysiology
Your new post is loading...
Scooped by Julien Hering, PhD
Scoop.it!

NIH Looking to Kick-Start Biotech Startups

NIH Looking to Kick-Start Biotech Startups | Pharmaceutics_R&D | Scoop.it

Agency will offer I-Corps entrepreneurship boot camps.

Last fall, microbial ecologist Kei Fujimura took time away from her lab work to hunt down people with inflammatory bowel disease on Facebook. The postdoctoral researcher at the University of California, San Francisco (UCSF), was doing a bit of market research, in hopes of starting a company that would offer people with Crohn’s disease and colitis personalized microbiome sequencing data that could help them manage their conditions. She and a fellow postdoc “thought we had a pretty good shot” at commercializing the idea, she says. (...) - by Kelly Servick, Science, 24 April 2014

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

New cures sought from old drugs

New cures sought from old drugs | Pharmaceutics_R&D | Scoop.it
Researchers to re-examine compounds shelved by industry.


Progeria is a rare, lethal disease that ages children so rapidly that they seem to be 80 years old when they are just 10. So patients and families celebrated the news last week of the first therapeutic success against the disease — as did advocates of the notion that abandoned drugs can rise again. A clinical trial has shown improved symptoms in children with the disease who used lonafarnib (L. B. Gordon Proc. Natl Acad. Sci. USA http://doi.org/jfz; 2012), a drug developed by Merck in the 1990s that failed against its original target, head and neck cancer. (...) - by Meredith Wadman, Nature News, 3 October, 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Legendary Drug Industry Executives Warn U.S. Science Cuts Endanger The Future - Forbes

Legendary Drug Industry Executives Warn U.S. Science Cuts Endanger The Future - Forbes | Pharmaceutics_R&D | Scoop.it

Biomedical research and innovation are crucial to improving America’s health, global competitiveness, and economic growth, as both President Obama and House Majority Leader Cantor have stressed in recent weeks. In the wake of the sequester, and as the President and Congress move ahead with budget negotiations, now is the time for both parties to translate into action their bipartisan commitment to our nation’s science investment by restoring the budgets of the National Institutes of Health (NIH) and other science agencies that support basic biomedical research in universities and medical schools in all 50 states – an area of federal spending that is highly productive and a critical investment. (...) - by Marc Tessier-Lavigne, President, The Rockefeller University and former Chief Scientific Officer, Genentech Inc. (left); P. Roy Vagelos, Chairman, Regeneron Pharmaceuticals, and Retired Chairman and CEO, Merck & Co., Inc. (center); and Elias ZerhouniPresident R&D Sanofi and former Director of the National Institutes of Health., Forbes, 03/06/2013

more...
No comment yet.